often lacks apparent mucosal lesions, making it difficult to detect in the early stages.
A wide range of genomic/epigenomic analyses has been conducted to identify therapeutic targets for gastric cancer. By combining whole exome sequencing (WES) and RNA-sequencing (RNA-seq) datasets, for instance, The Cancer Genome Atlas team proposed to divide gastric cancer into 4 subtypes: (i) Epstein-Barr virus-positive type, with a CpG island methylator phenotype and frequent PIK3CA nonsynonymous mutations; (ii) microsatellite instability-positive type, with a high mutation burden; (iii) chromosomal instability-positive type with TP53 alterations and amplification of tyrosine kinase genes; and (iv) genomically stable (GS)-type with frequent mutations within CDH1, RHOA and ARID1A. 8 The GS type is often associated with diffuse-type gastric cancer that significantly overlaps with SGC.
Somatic mutations within RHOA were also reported in 14%-25%
of diffuse-type gastric cancer. 9, 10 Such RHOA mutants are presumed to act in a dominant-negative manner to the wild-type protein, and, thereby, promote cell survival. 11 It is, however, unclear if these RHOA mutations are enriched in SGC.
Genome-wide mutation screening with next-generation sequencers (NGS) for SGC is severely hampered by low tumor contents by the markedly increased fibrous tissues in a given specimen.
SGC cell lines have been, therefore, useful resources to identify their transforming genes. FGFR2 gene was, for instance, shown to become amplified and oncogenic in an SGC cell line, KATO-III. 12 MET amplification is also reported to be present in some SGC cell lines. 13 To identify potential therapeutic targets in SGC, here we have conducted WES and RNA-seq for 2 SGC cell lines, OCUM-8 14 and OCUM-9. Interestingly, we revealed novel transforming fusion genes, CD44-IGF1R from the former cell line and BORCS5-ETV6 from the latter.
| MATERIAL S AND ME THODS

| Cell lines
Human embryonic kidney (HEK) 293T cells and mouse 3T3 fibroblasts were obtained from the ATCC (https://www.atcc.org). SGC cell lines, KATO-III and NUGC4, were purchased from Japanese 
| Next-generation sequencer analyses
Genomic DNA was isolated from each cell line and subjected to enrichment of exonic fragments with a SureSelect Human All Exon Kit v5 (Agilent) followed by nucleotide sequencing with the HiSeq2500 platform (Illumina) using the paired-end option.
Bioinformatics analyses were conducted as reported previously.
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Nonsynonymous mutations were called only when ≥10% of reads corresponded to the mutations at the positions with a total coverage of ≥20.
Total RNA was isolated from each cell line with the use of an RNeasy Mini Kit (Qiagen) and was subjected to RNA-seq using a 
| Functional assay
The cDNA of each gene was ligated into the pMX retroviral vector 
| Knockdown experiments with shRNA
Nucleotides corresponding to a shRNA against ETV6 were synthesized based on the shRNA (#sh-9528) from DECIPHER project another primer set (5′-GTCAGTGGTGGACCTGACCT-3′ and 5′-TGAGCTTGACAAAGTGGTCG-3′) for GAPDH.
| Accession code
The raw sequencing data have been deposited in the Japanese Genotype-Phenotype Archive (JGA, http://trace.ddbj.nig.ac.jp/ jga), which is hosted by DDBJ, under the accession number JGAS00000000179.
| RE SULTS
| Genomic analyses of OCUM-8
Whole exome sequencing of the genome of OCUM-8 and -9 was conducted with the mean coverage of 154× and 137×, respectively.
More than 96% of exome regions were sequenced at >20× coverage in both cell lines. Messenger RNA was also extensively sequenced with NGS for OCUM-8 and -9, yielding the total nucleotides of 38 and 41 gigabases, respectively.
As shown in Table S1 , after excluding nucleotide changes present in our in-house database for normal variations of human genome, we identified a total of 72 nonsynonymous mutations that are present in both exome and RNA-seq datasets of OCUM-8 (with a threshold of total coverage of ≥50× and of the mutation ratio of ≥25% in both datasets). Many of them have not been associ- 
| Discovery of a novel fusion gene, CD44-IGF1R
Because amplification of FGFR2 gene and augmentation of tyrosine kinase activity in its protein product plays an essential role in the proliferation of a SGC cell line, KATO-III, 12 we next analyzed chromosome copy number alterations (CNA) in OCUM-8.
The high coverage of our WES analysis enabled us to infer detailed CNV, revealing focal amplification of 11p13 and 15q26 loci encompassing CD44 and IGF1R genes, respectively ( Figure 1A ). To examine if this genomic alteration produces fusion proteins, we searched for fusion mRNAs among the RNA-seq dataset of OCUM-8. Interestingly, in-frame fusion transcripts were, indeed, found between CD44 and IGF1R and between IRS2 and EHF in OCUM-8 (Table S2) . By using RT-PCR, we obtained a full-length Figures 1D, S2B, S3) . Importantly, the expression of CD44-IGF1R gene is driven by the promoter of CD44 that is known to be abundantly expressed in cancer stem cell fractions. 17 
CD44-IGF1R
| CD44-IGF1R is a transforming kinase and therapeutic target in OCUM-8
The CD44-IGF1R transcript can encode a chimeric protein of 561 amino acid residues with a predicted molecular weight of 63 386, consisting of the signal peptide of CD44 and the transmembrane and the intracellular domains of IGF1R (Figure 2A ). Because fusion proteins of the IGF1R tyrosine kinase domain have rarely been reported, we assessed its transforming activity by using mouse 3T3
fibroblasts.
In the focus formation assay, as demonstrated in Figure 2B , expression of human wild-type CD44 did not induce transformed foci. were examined with antibodies to the IGF1R protein, revealing that broad bands of 65-90 kDa were detected with the antibody only in OCUM-8 ( Figure 2D , left panel). OCUM-8 cells were then incubated with linsitinib, a selective inhibitor against IGF1R tyrosine kinase activity. 18 As shown in the right panel of Figure 2D , immunoblot examination with antibodies to tyrosine-phosphorylated IGF1R revealed that phosphorylation of CD44-IGF1R
became decreased with linsitinib in a dose-dependent manner, while the protein amount of CD44-IGF1R was stable with the treatment.
We next investigated whether the enzymatic activity of CD44-IGF1R was essential for the survival of OCUM-8 cells. As demonstrated in Figure 2E , linsitinib strongly and rapidly inhibited the viability of OCUM-8 but did not affect that of CD44-IGF1R-negative OCUM-9 and KATO-III cells. 
| MET amplification in OCUM-9
Genome profiles of OCUM-9 were also investigated. As depicted in Table S3 , a total of 73 nonsynonymous mutations were detected in OCUM-9 with the same threshold from our WES and RNA-seq data. Interestingly, RHOA(L57V) found in OCUM-9 has been already shown to be associated with gastric cancer. 9 While the Leu-to-Val substitution at amino acid position 57 was demonstrated to be lossof-function, its relevance to gastric cancer remains elusive.
As in the case of OCUM-8, we assessed CNV in the genome of OCUM-9. Focal amplification was detected in chromosomes 2p, 7q
and 12p ( Figure 3A ). Because the 7q locus contains the MET gene, we further evaluated the copy number of MET with ddPCR among the control cells, KATO-III, NUGC4 and OCUM-1, -2M, -8, -9 and -12 cell lines ( Figure 3B ). MET is highly amplified in OCUM-9 (copy number = 31.4), whereas its amplification (copy number ≥ 4) was not observed in the other samples. The expression level of MET was further evaluated by the RNA-seq dataset, revealing its overexpression in OCUM-9 cells ( Figure 3C ).
Immunoblot analyses with antibodies to MET among OCUM-1, KATO-III, OCUM-8 and OCUM-9 confirmed the overexpression of MET protein ( Figure 3D , left panel). In OCUM-9 cells, MET is highly tyrosine-phosphorylated, but such phosphorylation becomes suppressed by the treatment with crizotinib, 19 an inhibitor for MET tyrosine kinase activity ( Figure 3D, right panel) . Next, OCUM-9 cells were cultured in the presence of crizotinib, showing that crizotinib rapidly inhibited cell viability in a dose-dependent manner ( Figure 3E ). Crizotinib, in contrast, did not affect that of OCUM-8 and KATO-III. In OCUM-9,
MET protein-tyrosine kinase is, thus, a suitable therapeutic target. 
| Other oncogenic alterations in OCUM-9
As shown in Table S2 , OCUM-9 has an in-frame fusion gene between BORCS5 (also known as LOH12CR1) and ETV6 (Table S2) 
| D ISCUSS I ON
Here we have examined oncogenic genomic events in 2 scirrhoustype cancer cell lines, OCUM-8 and OCUM-9, and found CD44-IGF1R
fusion-type oncogene in the former. IGF1R codes for a receptor for type I insulin-like growth factor, which is a transmembrane-type tyrosine kinase. Both IGF1 and IGF2 can bind to and activate the enzymatic potential of IGF1R, and thereby induce a plethora of intracellular signalings. Stimulation of IGF1R can lead to, for instance,
Genomic analyses of OCUM-9. A, From the WES data of OCUM-9, the logR ratio (LRR) is calculated as in Figure 1A . An amplification locus corresponding to MYCN, MET or ETV6 plus BORCS5 is indicated. The copy number (B) and the expression level (C) of MET are examined as in Figure 1B, activation of PI3K-AKT-mTOR, RAS-MAPK and IRS2 pathways.
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IGF1R also has anti-apoptotic ability, and, therefore, is considered to be an appropriate therapeutic target in cancer. 21 Furthermore, IGF1R may play an essential role in acquiring resistance to anti-cancer agents. In this manuscript, we have validated the genomic rearrangement that fuses the CD44 and IGF1R loci. Because the copy number of both genes are markedly increased ( Figure 1A ), complex rearrangements involving an amplicon containing CD44-IGF1R may take place in the OCUM-8 genome. CD44 is a cell-surface marker for cancer stem cells, 27 and is, indeed, highly expressed in our SGC cell lines (data not shown). In addition, CD44 is involved in the invasion process of SGC cells through the CD44-RAC1 pathway. 28 The promoter of CD44 should be, therefore, highly active in SGC cells, and may be an ideal partner for IGF1R to be in-frame IGF1R may, therefore, directly participate in carcinogenesis at a low frequency.
ETV6 belongs to the ETS family of transcription factors and is known to be fused to potential oncogenes, such as RUNX1
and NTRK3. 29, 30 ETV6 fusion to BORCS5 has not been reported yet. The focus formation assay revealed that BORCS5-ETV6 has a transforming ability as the wild-type ETV6, although the shape of foci generated by the former seems to be distinct from the latter ( Figure 4C ). BORCS5 is a component of the BLOC1-related complex, and functions to regulate lysosome localization. 31 Because BORCS5 contains an amino-terminal myristoylation signal, 32 In addition to BORCS5-ETV6, however, there are other oncogenic genomic alterations in OCUM-9. The MET tyrosine kinase gene is highly amplified in OCUM-9, and suppression of its enzymatic activity led to rapid cell death ( Figure 3A ,B, E). Furthermore, MYCN is markedly amplified and expressed in the same cell line ( Figures 3A and 4D) . Importantly, amplification of MYCN is frequently found in neuroblastoma, 33 and the forced expression of MYCN in dopamine β-hydroxylase-expressing cells in mice is sufficient to induce tumors resembling human neuroblastoma. 34 It is, therefore, likely that multiple oncogenic events contribute to the generation of OCUM-9.
We here reported novel oncogenic alterations in gastric cancer, IGF1R-fusion and ETV6-fusion genes, prevalence of which awaits further investigation. Detailed examination of other SGC cell lines may further decipher the molecular mechanisms underlying SGC and provide us therapeutic targets in this highly intractable malignancy.
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